Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

Spybiotech Ltd. has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP-01, a vaccine targeting human cytomegalovirus (CMV) using its hepatitis B virus-like-particle platform technology.

Benevolentai Ltd. has signed a strategic collaboration with Merck KGaA to identify novel drug candidates, initially for three targets in oncology, neurology and immunology.

Rohitukine is a chromone alkaloid with antiproliferative, anti-inflammatory, and immunomodulatory activities. Although several rohitukine derivatives are being investigated as potent anticancer leads, the potential antitumor activity of the naturally occurring rohitukine-N-oxide has yet to be evaluated.

Phaxiam Therapeutics SA has initiated a new preclinical development program targeting Klebsiella pneumoniae, which is responsible for severe infections and notable for its high resistance to antibiotics.

Influenza viruses possess the ability to quickly generate antigenic variation, making vaccines and anti-influenza drugs in use sometimes ineffective.